Rasio cepet: Exscientia plc (EXAI)

Exscientia plc (EXAI) operates as a scalable AI service for drug discovery, utilizing an asset-light model to sell molecule modeling algorithms to major pharmaceutical companies. This chart of the share price, which currently stands at 4.48, complements data on the robotization of biomedicine, where machine learning is replacing the routine labor of scientists. Meanwhile, early-stage biotech risks are mitigated by a broad spectrum of partnership agreements with industry leaders.

To objectively assess an issuer's solvency, a portfolio manager finds the analysis of the most liquid assets critically important. This metric compares cash and accounts receivable against short-term debts, completely excluding slow-moving inventories. The trend of the cash ratio demonstrates the company's ability to instantaneously settle obligations without selling off assets. For Exscientia plc (EXAI), which automates molecule discovery via AI, this confirms a financial cushion while scaling high-tech developments.